Ratio Therapeutics

Team Ratio was proud to take part in this year’s @PanCAN PurpleStride in support of the fight against pancreatic cancer. If you’d still like to get involved, donations remain open: secure.pancan.org/site/TR/Purple… #PancreaticCancer #PurpleStride #PanCAN

Ratio’s Kyle Powell will present at the Radiopharma Manufacturing Innovation Summit (Apr 28, Phoenix). Presentation Title - The Paperless Hot Cell: Building a Fully Digital GMP Ecosystem from the Ground Up in Radiopharma #program" target="_blank" rel="nofollow noopener">radiopharma-summit.com/radiopharma-ma… #Radiopharma #GMP

Only 10 DAYS away! We’re proud to support @PanCAN and their work to advance research and help patients & families. Join us or donate today: secure.pancan.org/site/TR/Purple… #PurpleStride #PanCAN #PancreaticCancer

We’re proud to sponsor the SARC Meeting Before #ASCO26 on May 29 in Chicago — a key forum for advancing sarcoma research through collaboration and innovation. Learn more & register: sarctrials.org/meetings/sarc-… #ASCO26 #SARC

Did you know April is #CancerControlMonth? We’re proud to support @PanCAN and their work to advance research and help patients & families. Join us or donate — your impact doubles today: secure.pancan.org/site/TR/Purple… #PurpleStride #PanCAN #PancreaticCancer

From rigorous training to hub-and-spoke distribution, #radiopharma manufacturing demands precision at every step. Ratio’s Scott Holbrook shares how we're raising the bar in a recent interview: pharmaceuticalonline.com/doc/raising-th… #Biotech #Manufacturing

Next week, Ratio’s CSO, John Babich, PhD, will be speaking at the 2026 PSMA & Beyond Conference, taking place March 26-27 in Los Angeles. Learn more and register: psmaconference.ucsf.edu #PSMA #Biotech #Radiopharma

Ratio today announced the appointment of Colin Hayward, MBBS, FFPM, as the company’s Chief Medical Officer. See the full news release here: prnewswire.com/news-releases/… #CMO #Appointment #Biotech #Radiopharma

In a recent article from Pharma Manufacturing, Ratio's Chief Commercial & Manufacturing Officer Scott Holbrook shared how we're thinking about scalable RLT manufacturing, logistics, and workforce readiness. bit.ly/4blRLcm #Radiopharmaceuticals #Radiopharma #Oncology

Earlier this month, our CEO Jack Hoppin, Ph.D., joined the #IO360Summit in Boston to discuss how imaging is evolving as a translational tool in immuno-oncology. Great conversations with leaders across the field. Thanks for a fantastic event! #Oncology #IO #Radiopharma

Today, Ratio CEO Jack Hoppin, Ph.D., returns to #IO360Summit (Feb 10-12 at the Sheraton Boston) to discuss the latest in immuno-oncology. Hope to see you there! Learn more: io360summit.com #Oncology #IO #Radiopharma

This #WorldCancerDay, we’re proud to support @PanCAN and their work to advance research and help patients & families. 💜 Join us or donate: secure.pancan.org/site/TR/Purple… #PurpleStride #PanCAN #PancreaticCancer

Our CEO Jack Hoppin joined industry leaders at the Sachs Oncology Forum to discuss the future of radioligand therapies. The panel's consensus? A breakthrough moment is on the horizon, with key infrastructure needs as RLT scales. Read in @pharmaphorum: pharmaphorum.com/rd/jpm-calm-st…

The radiopharmaceutical industry is experiencing unprecedented growth. Tomorrow, join our CEO Jack Hoppin at #JPM26 for "The Construction Boom in the Radiopharma Industry, "a roundtable exploring the future of radiopharma. #JPMWeek #JPM2026

This Saturday, our CEO, Jack Hoppin, Ph.D., will be participating in a panel at the Sachs Associates 11th Annual Oncology Innovation Forum titled, “Advancing Next-Gen Targeted Radiopharmaceuticals in Oncology.” sachsforum.com/11oif-about.ht… #Sachs_OIF #JPMWeek #JPM2026 #JPM26

2025 has been another incredible year for us at Ratio. As we dive into 2026, let’s take a look back at some of our highlights from the past year. We look forward to continuing our mission in developing best-in-class targeted radiotherapeutics in the new year! #2025Wrapped

Ratio announced dosing of the first cohort in the ATLAS trial, a Phase 1/2 open-label study evaluating the safety, tolerability, and efficacy of our lead radiopharmaceutical targeting FAP in patients with relapsed or refractory soft tissue sarcomas. prnewswire.com/news-releases/…

This #GivingTuesday, donations to Ratio’s PurpleStride team will be matched dollar-for-dollar! 💜 We’re proud to support @PanCAN and their work to advance research and help patients & families. Join us or donate! Your impact doubles today: secure.pancan.org/site/TR/Purple…

Happy Thanksgiving from all of us at Ratio! Wishing you and your loved ones a safe, restorative, and joyful holiday. 🧡

Radiopharmaceuticals are reshaping cancer care. In a new interview with @XTalks, Ratio CSO John Babich, PhD, shares how targeted therapies incorporating our Trillium™ platform are advancing precision, safety & patient experience. clinicaledge.xtalks.com/magazine/issue… #Oncology #Biotech